RESUMEN
PURPOSE: Evaluate and compare the retention time on the canine ocular surface of crosslinked hyaluronic acid (X-HA), linear hyaluronic acid (L-HA) and saline solution using fluorescent compounds (fluorescein sodium salt, Alexa Fluor 488 cadaverine and Alexa Fluor 488 maleimide). METHODS: 0.9% saline solution (SAL) was combined with fluorescein sodium salt. X-HA and L-HA were covalently modified using Alexa Fluor 488 reactive moieties. Eye drops were applied to 70 eyes of 35 dogs that were previously assessed and determined to have a normal ocular surface. Employing a blue light filter (450-490 nm), digital images were captured from instillation to 180 min. Images were analyzed to assess the percent of the total ocular area covered with green fluorescence at various time points. RESULTS: X-HA exhibited a dual phase behavior: A broad microgel coverage first, followed by accumulation in tear film meniscus and medial canthus in the second phase, remaining in contact with the ocular surface up to 180 min. Coverage with L-HA and SAL eye drops quickly migrated to the tear meniscus. No traces of the fluorescent compounds were observed by 45 min in eyes treated with SAL solution compound and, by 120 min, eyes treated with L-HA. CONCLUSIONS: X-HA exhibited a significantly increased ocular surface contact time with the ocular surface compared with L-HA and SAL. Not only could this indicate extended lubrication time but also supports the potential use of this compound as a method for topical sustained-release drug application.
Asunto(s)
Fluorofotometría , Ácido Hialurónico , Soluciones Oftálmicas , Animales , Ácido Hialurónico/administración & dosificación , Ácido Hialurónico/química , Perros , Soluciones Oftálmicas/química , Fluorofotometría/veterinaria , Fluorofotometría/métodos , Ojo/efectos de los fármacos , Masculino , FemeninoRESUMEN
Envisaging to improve the evaluation of ophthalmic drug products while minimizing the need for animal testing, our group developed the OphthalMimic device, a 3D-printed device that incorporates an artificial lacrimal flow, a cul-de-sac area, a moving eyelid, and a surface that interacts effectively with ophthalmic formulations, thereby providing a close representation of human ocular conditions. An important application of such a device would be its use as a platform for dissolution/release tests that closely mimic in vivo conditions. However, the surface that artificially simulates the cornea should have a higher resistance (10 min) than the previously described polymeric films (5 min). For this key assay upgrade, we describe the process of obtaining and thoroughly characterizing a hydrogel-based hybrid membrane to be used as a platform base to simulate the cornea artificially. Also, the OphthalMimic device suffered design improvements to fit the new membrane and incorporate the moving eyelid. The results confirmed the successful synthesis of the hydrogel components. The membrane's water content (86.25 ± 0.35 %) closely mirrored the human cornea (72 to 85 %). Furthermore, morphological analysis supported the membrane's comparability to the natural cornea. Finally, the performance of different formulations was analysed, demonstrating that the device could differentiate their drainage profile through the viscosity of PLX 14 (79 ± 5 %), PLX 16 (72 ± 4 %), and PLX 20 (57 ± 14 %), and mucoadhesion of PLXCS0.5 (69 ± 1 %), PLX16CS1.0 (65 ± 3 %), PLX16CS1.25 (67 ± 3 %), and the solution (97 ± 8 %). In conclusion, using the hydrogel-based hybrid membrane in the OphthalMimic device represents a significant advancement in the field of ophthalmic drug evaluation, providing a valuable platform for dissolution/release tests. Such a platform aligns with the ethical mandate to reduce animal testing and promises to accelerate the development of safer and more effective ophthalmic drugs.
Asunto(s)
Hidrogeles , Humanos , Hidrogeles/química , Soluciones Oftálmicas/química , Impresión Tridimensional , Córnea/efectos de los fármacos , Córnea/metabolismo , Administración Oftálmica , Membranas ArtificialesRESUMEN
Tear viscosity is a critical property affecting tear distribution and ocular surface stability. While not widely established as a primary diagnostic marker, deviations from normal viscosity can impact ocular health, potentially contributing to conditions such as dry eye syndrome. Despite their importance, traditional viscometers require sample volumes that are not feasible to use with tear volume. This research introduces a novel Quartz Crystal Microbalance (QCM)-based method for tear viscosity measurement, offering a viscometer prototype that operates with minimal sample volumes. Human tear samples, solutions used in artificial eye drops, and various commercial eye drop brands were evaluated. Results show that the QCM method aligns with established viscosity ranges. The average viscosity of healthy human tears was found to be 1.73 ± 0.61 cP, aligning with the typical range of 1-10 cP. Variability in the viscosities of eye drop can be attributed to differences in their chemical compositions. The QCM method offers benefits such as reduced sample consumption and rapid results, enhancing understanding of tear dynamics for ocular health. Further research with larger sample sizes is needed to establish normative viscosity values in healthy individuals and those with dry eye syndrome, which is crucial for validating the device's clinical efficacy.
Asunto(s)
Tecnicas de Microbalanza del Cristal de Cuarzo , Lágrimas , Viscosidad , Lágrimas/química , Tecnicas de Microbalanza del Cristal de Cuarzo/instrumentación , Tecnicas de Microbalanza del Cristal de Cuarzo/métodos , Humanos , Soluciones Oftálmicas/química , Síndromes de Ojo SecoRESUMEN
The literature reveals gaps in the availability of green analytical methods for assessing products containing gatifloxacin (GFX), a fluoroquinolone. Presently, method development is supported by tools such as the National Environmental Methods Index (NEMI) and Eco-Scale Assessment (ESA), which offer objective insights into the environmental friendliness of analytical procedures. The objective of this work was to develop and validate a green method by the NEMI and ESA to quantify GFX in eye drops using HPLC. The method utilized a C8 column (4.6 × 150 mm, 5 µm), with a mobile phase of purified water containing 2% acetic acid and ethanol (70:30, v/v). The injection volume was 10 µL and the flow rate was 0.7 mL/min in isocratic mode at 25°C, with detection performed at 292 nm. The method demonstrated linearity in the range of 2-20 µg/mL, and precision at intra-day (relative standard deviation [RSD] 1.44%), inter-day (RSD 3.45%), and inter-analyst (RSD 2.04%) levels. It was selective regarding the adjuvants of the final product (eye drops) and under forced degradation conditions. The method was accurate (recovery 101.07%) and robust. The retention time for GFX was approximately 3.5 min. The greenness of the method, as evaluated by the NEMI, showed four green quadrants, and by ESA, it achieved a score of 88.
Asunto(s)
Gatifloxacina , Tecnología Química Verde , Límite de Detección , Soluciones Oftálmicas , Gatifloxacina/análisis , Gatifloxacina/química , Cromatografía Líquida de Alta Presión/métodos , Reproducibilidad de los Resultados , Tecnología Química Verde/métodos , Modelos Lineales , Soluciones Oftálmicas/química , Soluciones Oftálmicas/análisis , Fluoroquinolonas/análisis , Fluoroquinolonas/químicaRESUMEN
The necessity of animal-free performance tests for novel ophthalmic formulation screening is challenging. For this, we developed and validated a new device to simulate the dynamics and physical-chemical barriers of the eye for in vitro performance tests of topic ophthalmic formulations. The OphthalMimic is a 3D-printed device with an artificial lacrimal flow, a cul-de-sac area, a support base, and a simulated cornea comprised of a polymeric membrane containing poly-vinyl alcohol 10 % (w/v), gelatin 2.5 % (w/v), and different proportions of mucin and poloxamer, i.e., 1:1 (M1), 1:2 (M2), and 2:1 (M3) w/v, respectively. The support base is designed to move between 0° and 50° to replicate the movement of an eyelid. We challenged the model by testing the residence performance of poloxamer®407 16 % and poloxamer®407 16 % + chitosan 1 % (PLX16CS10) gels containing fluconazole. The test was conducted with a simulated tear flow of 1.0 mL.min-1 for 5 min. The OphthalMimic successfully distinguished PLX16 and PLX16C10 formulations based on their fluconazole drainage (M1: 65 ± 14 % and 27 ± 10 %; M2: 58 ± 6 % and 38 ± 9 %; M3: 56 ± 5 % and 38 ± 18 %). In conclusion, the OphthalMimic is a promising tool for comparing the animal-free performance of ophthalmic formulations.
Asunto(s)
Soluciones Oftálmicas , Poloxámero , Poloxámero/química , Soluciones Oftálmicas/química , Administración Oftálmica , Fluconazol/administración & dosificación , Impresión Tridimensional , Córnea/efectos de los fármacos , Córnea/metabolismo , Animales , Quitosano/química , Alternativas a las Pruebas en Animales/métodos , Lágrimas/química , Humanos , Gelatina/químicaRESUMEN
PURPOSE: To evaluate the safety and potential healing efficacy of the topical ocular administration of a gelatin membrane containing usnic acid/liposomes (UALs) for corneal cicatrization. UALs have shown healing activity in animal models of dermal burn lesions. We evaluated the safety of topical ocular administration of UAL and its potential healing efficacy as an ophthalmic treatment on chemical lesions in rabbit eyes. METHOD: The Draize test was used to check for ocular toxicity and the score was zero at each observation, indicating the ocular safety of a gelatin membrane containing usnic acid/liposome. Its potential healing efficacy as an ophthalmic treatment on chemical lesions in rabbit eyes was also assessed. RESULTS: After epithelial removal and treatment with UAL, there was a 49.4 % reduction in injury under in vivo conditions compared with a 36.6 % reduction in the control, a gelatin membrane containing liposome without usnic acid. Histological analysis of ocular surface chemical injury-tissue sections after treatment with UAL supported these observations. The corneal expression of VEGF and TGF-ß1increased by 70 % and 50 % respectively following treatment with UAL gelatin membrane. CONCLUSION: These results indicate the potential therapeutic application of UAL gelatin membranes as an ophthalmic treatment that may be used for corneal cicatrization.
Asunto(s)
Benzofuranos/administración & dosificación , Cicatriz/tratamiento farmacológico , Córnea/efectos de los fármacos , Sistemas de Liberación de Medicamentos , Cicatrización de Heridas/efectos de los fármacos , Administración Oftálmica , Animales , Benzofuranos/química , Pollos , Córnea/irrigación sanguínea , Femenino , Gelatina/administración & dosificación , Gelatina/química , Liposomas/administración & dosificación , Liposomas/química , Neovascularización Fisiológica/efectos de los fármacos , Soluciones Oftálmicas/químicaRESUMEN
Devices such as contact lenses and collagen shields have been used to improve the antibiotic bioavailability of eye drops formulations in the treatment of ulcerative keratitis. Nevertheless, these devices are not sustained drug delivery systems, and a combination with eye drops is necessary. In animal patients, it requires constant supervision by trained personnel to avoid device loss, which increases the cost of treatment. In this study, PVA/anionic collagen membranes containing ciprofloxacin or tobramycin were prepared using two different methodologies, and the release, physical and antimicrobial properties were evaluated. The membrane containing ciprofloxacin was selected as a sustained drug delivery system with antibacterial activity against Staphylococcus aureus and Escherichia coli during 48 h. Despite to be opaque, due to its heterogeneous morphology, this membrane had the adequate mechanical strength, water content, hydrophilicity, water vapor permeability, and surface pH to interact with cornea without causing discomfort. In the surface of this membrane it was observed dispersed collagen fibrils which could serve as a substrate for corneal proteinases, contributing to the reduction in stromal damage and enhancing the epithelium regeneration. These results encourage the idea these membranes are new cost-effective and safe alternatives to treat corneal ulcers in animal patients.
Asunto(s)
Antibacterianos/química , Ciprofloxacina/química , Colágeno/química , Úlcera de la Córnea/tratamiento farmacológico , Portadores de Fármacos/química , Soluciones Oftálmicas/química , Alcohol Polivinílico/química , Antibacterianos/farmacología , Materiales Biocompatibles/química , Ciprofloxacina/farmacología , Lentes de Contacto , Córnea/efectos de los fármacos , Composición de Medicamentos , Escherichia coli/efectos de los fármacos , Humanos , Fenómenos Mecánicos , Soluciones Oftálmicas/farmacología , Permeabilidad , Staphylococcus aureus/efectos de los fármacos , Propiedades de Superficie , Tobramicina/farmacología , Agua , HumectabilidadRESUMEN
A novel automated method for the determination of boron based on the use of pulsed flows was developed and applied to the determination of this element in samples of tap water, ocean water and eye drops. The method was implemented by means of a multi-pumping system consisting of three solenoid micropumps and a photometric detector and exploits the reaction of azomethine-H in the presence of boron. The system runs under control of an open-source microcontroller. The main operational parameters were optimized. Given the particular kinetics of the reaction, a stopped-flow period (1 or 5min) was included to allow for color development. The method presents linearity in the range 0.35-3.0mgL-1, good precision (sr<3%), and detection and quantification limits of 0.10 and 0.35mgL-1 respectively. Samples of tap water or eye drops could be successfully analyzed employing a 1-minute stop time, providing a maximum sampling frequency of 32 samples h-1. In order to overcome matrix effect caused by the high saline concentration, ocean water samples required stop times of 5min, providing a sampling frequency of 10 samples h-1. Recoveries of 102% (eye drops), 94% (drinking water) and 93% (ocean water) were obtained. The method was considered accurate and fit for the purpose.
Asunto(s)
Boro/análisis , Técnicas de Química Analítica/instrumentación , Agua Potable/química , Soluciones Oftálmicas/química , Agua de Mar/químicaRESUMEN
The aim of this work was to design and characterize cross-linked hyaluronic acid (HA)-itaconic acid (IT) films loaded with dexamethasone sodium phosphate salt (DEX) for topical therapy of inflammatory ocular surface diseases. Films were chemically cross-linked with polyethylene glycol diglycidyl ether (PEGDE), then physical and mechanical characterization by stress-strain, X-ray diffraction, X-ray fluorescence spectrometry and swelling assays was conducted. A sequential in vitro therapeutic efficacy model was designed to assess changes in interleukin (IL)-6 production in an inflamed human corneal epithelial (HCE) cell line after film exposure. Changes in cell proliferation after film exposure were assessed using the alamarBlue(®) proliferation assay. Experimental findings showed desirable mechanical properties and in vitro efficacy to reduce cell inflammation. A moderately decreased proliferation rate was induced in HCE cells by DEX-loaded films, compared to commercial DEX eye drops. These results suggest that DEX and HA have opposite effects. The sequential in vitro therapeutic efficacy model arises as an efficient tool to study drug release from delivery systems by indirect measurement of a biological response.
Asunto(s)
Córnea/efectos de los fármacos , Dexametasona/análogos & derivados , Ácido Hialurónico/química , Soluciones Oftálmicas/administración & dosificación , Soluciones Oftálmicas/química , Administración Tópica , Línea Celular , Proliferación Celular/efectos de los fármacos , Dexametasona/administración & dosificación , Dexametasona/química , Humanos , Inflamación/tratamiento farmacológico , Succinatos/químicaRESUMEN
PURPOSE: To evaluate the effectiveness of topical 1% cyclosporine eye drops diluted in either of the two vehicles-olive and linseed oil-and that of the oils themselves in treating experimentally-induced keratoconjunctivitis sicca (KCS) in rabbits. METHODS: KCS was induced in 25 New Zealand rabbits using 1% atropine sulfate eye drops for 7 days before treatment and throughout the treatment period (12 weeks). The rabbits were divided into five groups: one control (C) group without KCS induction and four treatment groups in which KCS was induced and treated topically with olive oil (O), linseed oil (L), cyclosporine in olive oil (CO), and cyclosporine in linseed oil (CL). The animals were evaluated using Schirmer tear test 1 (STT), the fluorescein test (FT), tear-film break-up time (TBUT), the rose bengal test (RBT), and histopathological analysis. RESULTS: Values of STT and TBUT significantly decreased 1 week post-induction (p<0.05) and were similar to initial values after the 4th week of treatment, in all groups. After KCS induction, there was significantly less corneal damage in group L than in group CL, as assessed FT and RBT. Histopathology demonstrated that Groups L and CL presented less edema and corneal congestion. There was no significant difference in the goblet cell density (cells/mm2) between the groups (p=0.147). CONCLUSION: Cyclosporine diluted in olive oil or linseed oil was effective in the treatment of KCS, although it had better efficacy when diluted in linseed oil. Linseed oil presented better effectiveness, whether associated or not, than olive oil. These results may contribute to the creation of novel topical ophthalmic formulations for KCS treatment in future.
Asunto(s)
Ciclosporina/administración & dosificación , Inmunosupresores/administración & dosificación , Queratoconjuntivitis Seca/tratamiento farmacológico , Aceite de Linaza/administración & dosificación , Aceite de Oliva/administración & dosificación , Soluciones Oftálmicas/administración & dosificación , Administración Oftálmica , Animales , Conjuntiva/efectos de los fármacos , Conjuntiva/patología , Córnea/efectos de los fármacos , Córnea/patología , Ciclosporina/química , Portadores de Fármacos/administración & dosificación , Combinación de Medicamentos , Fluoresceína , Células Caliciformes/efectos de los fármacos , Inmunosupresores/química , Queratoconjuntivitis Seca/patología , Masculino , Soluciones Oftálmicas/química , Conejos , Reproducibilidad de los Resultados , Lágrimas/metabolismo , Resultado del TratamientoRESUMEN
ABSTRACTPurpose:To evaluate the effectiveness of topical 1% cyclosporine eye drops diluted in either of the two vehicles-olive and linseed oil-and that of the oils themselves in treating experimentally-induced keratoconjunctivitis sicca (KCS) in rabbits.Methods:KCS was induced in 25 New Zealand rabbits using 1% atropine sulfate eye drops for 7 days before treatment and throughout the treatment period (12 weeks). The rabbits were divided into five groups: one control (C) group without KCS induction and four treatment groups in which KCS was induced and treated topically with olive oil (O), linseed oil (L), cyclosporine in olive oil (CO), and cyclosporine in linseed oil (CL). The animals were evaluated using Schirmer tear test 1 (STT), the fluorescein test (FT), tear-film break-up time (TBUT), the rose bengal test (RBT), and histopathological analysis.Results:Values of STT and TBUT significantly decreased 1 week post-induction (p<0.05) and were similar to initial values after the 4th week of treatment, in all groups. After KCS induction, there was significantly less corneal damage in group L than in group CL, as assessed FT and RBT. Histopathology demonstrated that Groups L and CL presented less edema and corneal congestion. There was no significant difference in the goblet cell density (cells/mm2) between the groups (p=0.147).Conclusion:Cyclosporine diluted in olive oil or linseed oil was effective in the treatment of KCS, although it had better efficacy when diluted in linseed oil. Linseed oil presented better effectiveness, whether associated or not, than olive oil. These results may contribute to the creation of novel topical ophthalmic formulations for KCS treatment in future.
RESUMOObjetivo:Avaliar a eficácia do uso tópico do colírio de ciclosporina 1% em dois veículos, óleo de oliva e linhaça, e dos óleos separados, no tratamento da ceratoconjuntivite seca experimentalmente induzida (KCS) em coelhos.Método:Vinte e cinco coelhos Nova Zelândia foram induzidos para KCS com colírio de sulfato de atropina a 1% por sete dias antes e durante o período de tratamento (12 semanas) e foram divididos em 5 grupos, um grupo controle (C), sem indução de KCS e quatro grupos de tratamento tópico com ciclosporina em óleo de oliva (CO), ciclosporina em óleo de linhaça (CL), óleo de oliva (O) e óleo de linhaça (L). Os animais foram avaliados utilizando o teste lacrimal de Schirmer I (STT), teste de fluoresceína (FT), teste de ruptura do filme lacrimal (TBUT), teste de rosa bengala (RBT) e análise histopatológica.Resultados:Os valores de TBUT e STT diminuíram significativamente uma semana pós-indução da KCS (p<0,05) e foram semelhantes aos valores iniciais após a quarta semana de tratamento, em todos os grupos. Após a indução de KCS, houve menor dano na córnea no grupo L em relação ao grupo CL, quando avaliados FT e RBT. A histopatologia demonstrou que os grupos L e CL apresentaram menos edema e congestão da córnea. Não houve diferença significativa na densidade das células caliciformes (células/mm2) entre os grupos (p=0,147).Conclusão:Ciclosporina diluída em óleo de oliva ou linhaça foi eficiente no tratamento da CCS, porém teve uma melhor eficácia quando diluída no óleo de linhaça. O óleo de linhaça, isoladamente ou associado, apresentou melhor eficácia quando comparado ao óleo de oliva. Estes resultados podem contribuir no futuro com novas formulações oftálmicas tópicas no tratamento da CCS.
Asunto(s)
Animales , Masculino , Conejos , Ciclosporina/administración & dosificación , Inmunosupresores/administración & dosificación , Queratoconjuntivitis Seca/tratamiento farmacológico , Aceite de Linaza/administración & dosificación , Aceite de Oliva/administración & dosificación , Soluciones Oftálmicas/administración & dosificación , Administración Oftálmica , Conjuntiva/efectos de los fármacos , Conjuntiva/patología , Córnea/efectos de los fármacos , Córnea/patología , Ciclosporina/química , Combinación de Medicamentos , Portadores de Fármacos/administración & dosificación , Fluoresceína , Células Caliciformes/efectos de los fármacos , Inmunosupresores/química , Queratoconjuntivitis Seca/patología , Soluciones Oftálmicas/química , Reproducibilidad de los Resultados , Resultado del Tratamiento , LágrimasRESUMEN
This paper deals with the characterization study of topical and intraocular biocompatibility and toxicity of cationic hydroxyethylcellulose Polyquaternium 10 (PQ10). It also evaluates the rheological properties of gels. The cytotoxicity assays were done in two cell lines: HEp-2 and VERO (human larynx epidermoid carcinoma cell and African green monkey kidney cells respectively). For the in vivo study, New Zealand albino rabbits were used. The in vitro cytotoxic activity of PQ10 shows no statistically significant differences in relation to the control of hydroxypropylmethylcellulose (HPMC) in any of the cell lines used in this study. Similarly, the signs of inflammation observed after treatment showed no significant difference between the groups of animals treated with the polymer compared to the control group. Normal histological characteristics were seen in both groups with no histological inflammatory reaction. After 1 month of the intracameral application of 2% PQ10 (treatment group) or 0.3% HPMC (control group), electroretinograms showed similar levels of a- and b-waves latencies and amplitude. In summary, PQ10 gel was well tolerated in these experiments, with proper monitoring, it could stand as a new alternative in the development of ophthalmic viscosurgical devices.
Asunto(s)
Celulosa/análogos & derivados , Ojo/efectos de los fármacos , Ojo/patología , Soluciones Oftálmicas/química , Soluciones Oftálmicas/toxicidad , Compuestos de Amonio Cuaternario/química , Compuestos de Amonio Cuaternario/toxicidad , Administración Oftálmica , Administración Tópica , Animales , Materiales Biocompatibles/química , Materiales Biocompatibles/toxicidad , Celulosa/química , Celulosa/toxicidad , Chlorocebus aethiops , Módulo de Elasticidad , Geles/química , Geles/toxicidad , Células Hep G2 , Humanos , Técnicas In Vitro , Ensayo de Materiales , Conejos , Células Vero , ViscosidadRESUMEN
A new stability-indicating RP-HPLC assay method was developed and validated for quantitative determination of loteprednol etabonate in bulk drugs and in ophthalmic suspensions in the presence of degradation products generated from forced degradation studies. The system consisted of Agilent Technologies Zorbax Eclipse XDB-Phenyl 5 µm 4.6 × 250 mm, and detection was performed at 244 nm. The mobile phase consisted of water-acetonitrile-acetic acid (34.5:65.0:0.5, v/v/v) run at a flow rate of 1 mL/min and maintained at room temperature. The calibration curve was linear from 30 to 70 µg/mL with r > 0.999. Accuracy (mean recovery 100.78%) and precision were found to be satisfactory. Stress conditions including acid and alkali hydrolysis, water stress, oxidation, photolysis and heat were applied. The degradation products did not interfere with the detection of loteprednol etabonate, thus the method can be considered as a stability-indicating method. The proposed method can be used for quality control assay of loteprednol etabonate in bulk drug and in ophthalmic suspensions and for stability studies as a result of the ability of the method to separate loteprednol etabonate from its degradation products and excipients.
Asunto(s)
Androstadienos/química , Cromatografía Líquida de Alta Presión/métodos , Soluciones Oftálmicas/química , Cromatografía de Fase Inversa/métodos , Estabilidad de Medicamentos , Etabonato de Loteprednol , Control de CalidadRESUMEN
OBJECTIVE: To develop non-toxic aqueous ocular drug delivery systems containing prednisolone by means of its nanoencapsulation. MATERIALS AND METHODS: Nanocapsules were prepared by interfacial deposition of preformed polymer [poly(ε-caprolactone) or Eudragit® RS100]. Particle size distribution was determined by laser diffractometry, photon correlation spectroscopy and nanoparticle tracking analysis. Ocular irritation and cytotoxicity were evaluated in vitro on the chorioallantoic membrane (CAM) and rabbit corneal epithelial cell line, respectively. RESULTS AND DISCUSSION: Nanocapsules showed mean particle sizes between 100 and 300 nm and prednisolone encapsulation efficiency of around 50%. Controlled release of prednisolone occurred for 5 h for both formulations according to the biexponential model. Both formulations were found to be non-irritant in the CAM test and non-cytotoxic toward rabbit corneal epithelial cells. CONCLUSIONS: Encapsulation of prednisolone in nanocapsules was reported for the first time, being suitable for producing eye drops for the treatment of ocular inflammatory and no eye toxicity was indicated.
Asunto(s)
Antiinflamatorios , Conjuntivitis/tratamiento farmacológico , Sistemas de Liberación de Medicamentos , Nanocápsulas/química , Soluciones Oftálmicas , Prednisolona , Resinas Acrílicas/química , Animales , Antiinflamatorios/química , Antiinflamatorios/farmacología , Línea Celular , Embrión de Pollo , Conjuntivitis/patología , Evaluación Preclínica de Medicamentos , Soluciones Oftálmicas/química , Soluciones Oftálmicas/farmacología , Poliésteres/química , Prednisolona/química , Prednisolona/farmacología , ConejosRESUMEN
Avaliaram-se as apresentações comerciais de colírios anestésicos aplicados em 63 coelhos da raça Nova Zelândia, distribuídos em três grupos (G1, G2 e G3) de 21 animais cada e que receberam instilação de uma gota em cada olho seis vezes ao dia. Os animais do G1 foram tratados com colírio de cloridrato de proparacaína a 0,5%; os do G2, com colírio de cloridrato de tetracaína a 1% associado à fenilefrina a 0,1%; e os do G3, com solução fisiológica. Cada grupo foi subdividido em três subgrupos com sete animais cada, os quais foram tratados por três, sete e 15 dias. No final de cada tratamento, dois animais de cada subgrupo foram sacrificados para exame histológico de fragmentos retirados da conjuntiva, da terceira pálpebra e das pálpebras. Observou-se, ao exame clínico, episclerite em graus diversos em 100% dos animais do G1, no terceiro, sétimo e 15º dia, e em apenas 17,8% nos do G2, nestes mesmos dias. Ao exame microscópico, observaram-se aumento do número de células califormes, proliferação de folículos linfoides, aumento do número de eosinófilos e aumento do espaço intersticial nas pálpebras dos animais do G1. Pôde-se concluir que o colírio de tetracaína a 1% associado à fenilefrina a 0,1% promoveu maior toxicidade à conjuntiva ocular e às pálpebras de coelhos quando comparado ao colírio de proparacaína a 0,5%.
This work aimed to evaluate commercial presentations of anesthetic eye drops in sixty three New Zealand rabbits which were separated equally in three groups (G1, G2 and G3). The G1 group was treated with 0.5% proparacaine chloridrate eye drop, G2 group with 1% tetracaine chloridrate associated with 0.1% phenylephrine eye drop and G3 group with 0.9% physiologic solution eye drop. All of them received one drop in each eye six times a day. Each group was subdivided into three subgroups (seven rabbits), which are treated for 3, 7 and 15 days. At the end of each treatment, two animals in each subgroup were subject to euthanasia, for the purpose of conjunctiva, eyelids and third eyelids histological evaluation. At the clinical exam, different grades of episcleritis were found in all rabbits in G2 group and only in 17.8% of the rabbits in G1 group. Eye and eyelid histologic evaluation of G2 group revealed an upgrade of goblet cells and eosinophil number, lymphoid follicle proliferation and increase of interstitial space in the eyelids. We could conclude that 1% tetracaine associated with 0.1% phenylephrine eye drop caused more eyelid and ocular conjunctiva toxicity than 0.5% proparacaine eye drop.
Asunto(s)
Animales , Conejos , Adyuvantes Anestésicos/análisis , Conejos/anatomía & histología , Soluciones Oftálmicas/análisis , Soluciones Oftálmicas/química , Tetracaína/análisis , Tetracaína/historia , Blefaritis/diagnóstico , Blefaritis/veterinariaRESUMEN
Chitosan of high molar mass and with 82% deacetylation was sulfated using two procedures and characterized. In the first method sample chitosan-S1 was produced using chlorosulfonic acid as the sulfating agent and N,N-dimethylformamide as the medium, and in the second method (chitosan-S2) formic acid was also used. The degrees of sulfation were 0.87 (chitosan-S1) and 0.67 (chitosan-S2). FTIR spectra showed bands at 1230, 800 and 580 cm(-1), attributed to sulfation. Moisture content followed the order: chitosan-S-0.87>chitosan-S-0.67>chitosan. Chain depolymerization was verified by GPC. Aqueous solutions showed pseudoplastic behavior and the viscosity at a concentration of 0.3% (w/v) was higher than that of healthy human tears (close to 3 mPas at shear rate 130 s(-1)). Substitutions in the C2NH and in C6OH groups were verified by NMR. Antimicrobial activity against Staphylococcus aureus and Pseudomonas aeruginosa was not observed. Considering that chitosan-S-0.67 had a higher solubility, less chain depolymerization, higher yield and better thermal stability in comparison with chitosan-S-0.87, the derivative with DS 0.67 offered the greatest potential for use in formulations of tear substitutes.
Asunto(s)
Antibacterianos/química , Antibacterianos/farmacología , Quitosano/química , Quitosano/farmacología , Soluciones Oftálmicas/química , Soluciones Oftálmicas/farmacología , Sulfatos/química , Humanos , Concentración Osmolar , Pseudomonas aeruginosa/efectos de los fármacos , Reología , Staphylococcus aureus/efectos de los fármacosRESUMEN
Avaliaram-se as apresentações comerciais de colírios anestésicos aplicados em 63 coelhos da raça Nova Zelândia, distribuídos em três grupos (G1, G2 e G3) de 21 animais cada e que receberam instilação de uma gota em cada olho seis vezes ao dia. Os animais do G1 foram tratados com colírio de cloridrato de proparacaína a 0,5%; os do G2, com colírio de cloridrato de tetracaína a 1% associado à fenilefrina a 0,1%; e os do G3, com solução fisiológica. Cada grupo foi subdividido em três subgrupos com sete animais cada, os quais foram tratados por três, sete e 15 dias. No final de cada tratamento, dois animais de cada subgrupo foram sacrificados para exame histológico de fragmentos retirados da conjuntiva, da terceira pálpebra e das pálpebras. Observou-se, ao exame clínico, episclerite em graus diversos em 100% dos animais do G1, no terceiro, sétimo e 15º dia, e em apenas 17,8% nos do G2, nestes mesmos dias. Ao exame microscópico, observaram-se aumento do número de células califormes, proliferação de folículos linfoides, aumento do número de eosinófilos e aumento do espaço intersticial nas pálpebras dos animais do G1. Pôde-se concluir que o colírio de tetracaína a 1% associado à fenilefrina a 0,1% promoveu maior toxicidade à conjuntiva ocular e às pálpebras de coelhos quando comparado ao colírio de proparacaína a 0,5%.(AU)
This work aimed to evaluate commercial presentations of anesthetic eye drops in sixty three New Zealand rabbits which were separated equally in three groups (G1, G2 and G3). The G1 group was treated with 0.5% proparacaine chloridrate eye drop, G2 group with 1% tetracaine chloridrate associated with 0.1% phenylephrine eye drop and G3 group with 0.9% physiologic solution eye drop. All of them received one drop in each eye six times a day. Each group was subdivided into three subgroups (seven rabbits), which are treated for 3, 7 and 15 days. At the end of each treatment, two animals in each subgroup were subject to euthanasia, for the purpose of conjunctiva, eyelids and third eyelids histological evaluation. At the clinical exam, different grades of episcleritis were found in all rabbits in G2 group and only in 17.8% of the rabbits in G1 group. Eye and eyelid histologic evaluation of G2 group revealed an upgrade of goblet cells and eosinophil number, lymphoid follicle proliferation and increase of interstitial space in the eyelids. We could conclude that 1% tetracaine associated with 0.1% phenylephrine eye drop caused more eyelid and ocular conjunctiva toxicity than 0.5% proparacaine eye drop.(AU)
Asunto(s)
Animales , Conejos , Conejos/anatomía & histología , Adyuvantes Anestésicos/análisis , Tetracaína/análisis , Tetracaína/historia , Soluciones Oftálmicas/análisis , Soluciones Oftálmicas/química , Blefaritis/diagnóstico , Blefaritis/veterinariaRESUMEN
Fungal keratitis is a serious disease that can lead to loss of vision. Unfortunately, current therapeutic options often result in poor bioavailability of antifungal agents due to protective mechanisms of the eye. The aim of this work was to evaluate the potential of a chitosan solution as well as an in situ gel-forming system comprised of poloxamer/chitosan as vehicles for enhanced corneal permeation and sustained release of fluconazole (FLU). For this, in vitro release and ex vivo corneal permeation experiments were carried out as a function of chitosan concentration from formulation containing the chitosan alone and combined with the thermosensitive polymer, poloxamer. Microdialysis was employed in a rabbit model to evaluate the in vivo performance of the formulations. The in vitro release studies showed the sustained release of FLU from the poloxamer/chitosan formulation. Ex vivo permeation studies across porcine cornea demonstrated that the formulations studied have a permeation-enhancing effect that is independent of chitosan concentration in the range from 0.5 to 1.5% w/w. The chitosan solutions alone showed the greatest ex vivo drug permeation; however, the poloxamer/chitosan formulation presented similar in vivo performance than the chitosan solution at 1.0%; both formulations showed sustained release and about 3.5-fold greater total amount of FLU permeated when compared to simple aqueous solutions of the drug. In conclusion, it was demonstrated that both the in situ gelling formulation evaluated and the chitosan solution are viable alternatives to enhance ocular bioavailability in the treatment of fungal keratitis.
Asunto(s)
Quitosano/administración & dosificación , Fluconazol/administración & dosificación , Geles/administración & dosificación , Soluciones Oftálmicas/administración & dosificación , Poloxámero/administración & dosificación , Administración Tópica , Animales , Antifúngicos/administración & dosificación , Antifúngicos/química , Química Farmacéutica/métodos , Quitosano/química , Córnea/efectos de los fármacos , Córnea/metabolismo , Preparaciones de Acción Retardada , Sistemas de Liberación de Medicamentos/métodos , Excipientes/administración & dosificación , Excipientes/química , Infecciones Fúngicas del Ojo/tratamiento farmacológico , Infecciones Fúngicas del Ojo/metabolismo , Fluconazol/química , Geles/química , Microdiálisis/métodos , Soluciones Oftálmicas/química , Permeabilidad/efectos de los fármacos , Poloxámero/química , Conejos , Porcinos , TemperaturaRESUMEN
PURPOSE: To investigate the in vitro pH, osmolarity, spectral, and photostability properties of nine vital dyes for vitreoretinal surgery. METHODS: Nine dyes-indocyanine green (ICG), trypan blue (TB), brilliant blue (BriB), bromophenol blue (BroB), Congo red (CR), light green (LG), fast green (FG), indigo carmine (IC) and Evans blue (EB)-diluted in three solvents (saline solution, glucose 5%, and water) were tested for osmolarity and pH. Spectrophotometry was used to determine absorbance properties of 27 solutions. Irradiance emission spectra of seven endoillumination light sources and fiber-optics were compared with dye absorbance curves. RESULTS: Dye osmolarity in saline solution and glucose 5% varied widely (257-385 mOsm) and was lower (0-54 mOsm) when dyes were dissolved in water. Dyes diluted in three solvents showed pH values varying from 2.6 to 9.85. ICG, LG, TB, BroB, CR, and IC demonstrated different absorbances, depending on the solvent. BriB and FG showed similar absorbance curves with different solvents. Spectrophometric analysis showed that all dyes except ICG had remarkable spectral overlap with the light sources. Among endoillumination fiber-optics, overlap was greatest with dual-output illumination with an integrated laser pathway and least with a mercury vapor lamp. CONCLUSIONS: Vital dyes showed variable osmolarity and pH, which also depended on the solvent used. Interaction of light from endoillumination source and vital dye may increase or decrease the risk for toxicity, making appropriate selection of both a desirable way to minimize the risk for phototoxic effects.
Asunto(s)
Colorantes/química , Colorantes/efectos de la radiación , Luz , Vitrectomía , Estabilidad de Medicamentos , Membrana Epirretinal/diagnóstico , Membrana Epirretinal/cirugía , Concentración de Iones de Hidrógeno , Soluciones Oftálmicas/química , Soluciones Oftálmicas/efectos de la radiación , Concentración Osmolar , Espectrofotometría Ultravioleta , Coloración y Etiquetado/métodosRESUMEN
Controlled delivery of drugs is a major issue in the treatment of ocular diseases, such as in the treatment of uveitis. In this study, dexamethasone acetate, an important type of corticoid used in the treatment of some uveitis, was incorporated into biodegradable polyurethanes (PU) having different macromolecular architectures. The biodegradable polyurethanes were obtained by preparing PU aqueous dispersions having poly(caprolactone) and/or poly(ethylene glycol) as soft segments. The drug was incorporated into the polymer by dissolving it in the PU aqueous dispersion. FTIR results showed the presence of the drug in the polymer with its original chemical structure. Small angle X-ray scattering (SAXS) results were explored to show that the incorporation of dexamethasone acetate led to the modification of the nanostructure of the polyurethane having only poly(caprolactone) as the soft segment, while the drug did not change significantly the microphase separated structure of PU having both poly(caprolactone) and poly(ethylene glycol) as soft segments. The evaluation of the release of the drug in vitro demonstrated that the obtained biodegradable polyurethanes were well succeeded in delivering dexamethasone acetate at an almost constant rate for 53 weeks. The presence of poly(ethylene glycol) together with poly(caprolactone) as soft segment in biodegradable PU was able to increase the rate of dexamethasone acetate release when compared to the rate of drug release from PU having only poly(caprolactone).